Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xynomic Pharmaceuticals Holdings, Inc.

http://xynomicpharma.com

Latest From Xynomic Pharmaceuticals Holdings, Inc.

Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.

Commercial Companies

Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began

But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.

StartUps and SMEs Financing

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Bison Capital Acquisition Corp.
    • Xynomic Pharmaceuticals, Inc.
UsernamePublicRestriction

Register